Novavax, Inc. (Nasdaq: NVAX), a global company advancing protein-based vaccines with its Matrix-M™ adjuvant, today announced progress in Q4 2024 advancing its corporate growth strategy through ...

Shares of this vaccine maker have returned -13.6% over the past month versus the Zacks S&P 500 composite's +1% change. The Zacks Medical - Biomedical and Genetics industry, to which Novavax ...

The first human bird flu death in the US has Moderna's vaccine development in focus for investors this week. Novavax (NVAX) witnessed a jump in share price last session on above-average trading ...

Novavax (NVAX) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of the factors that might affect the near-term performance of the stock.

Novavax (NVAX) closed the most recent trading day at $8.45, moving +0.24% from the previous trading session. The stock trailed the S&P 500, which registered a daily gain of 0.72%. Meanwhile, the Dow ...

A nasal vaccine for COVID-19 – based on technology developed at Washington University in St. Louis – is poised to enter a phase 1 clinical trial in the U.S. after an investigational new drug ...

The UK approval marks the fourth regulatory approval Valneva has received for its single-shot chikungunya vaccine. The vaccine is currently approved in the United States (U.S.) 2, Europe 3 and Canada ...

A nasal vaccine for COVID-19 – based on technology developed at Washington University in St. Louis – is poised to enter a phase 1 clinical trial in the U.S. after an investigational new drug ...

The owner of Long Island’s last remaining duck farm is pressing federal regulators to allow currently available vaccines to help protect U.S. poultry farms in the wake a devastating bird-flu ...

KAMPALA, Uganda — Ugandan authorities on Monday began a clinical trial of a vaccine against the Sudan strain of Ebola that has killed one person in the outbreak declared last week. This is the ...

Back in November 2023, pharmaphorum travelled to Uppsala, Sweden, for a Novavax press conference, the company celebrating a decade of doing what it does best: vaccines. From COVID-19 to malaria ...